Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for overweight or obesity in adults with type 1 diabetes
ACTRN12624001369516Phase 2Recruiting
- Sponsor
- Sydney Local Health District
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tirzepatide in diabetes mellitus type 1 (T1D) and obesity (2 arms), sponsored by Sydney Local Health District. Primary endpoints: Change in body weight (%) and Change in percent Time in Range. Started Feb 2025; status: recruiting.
02
Drugs
03
Conditions
diabetes mellitus type 1 (T1D)obesity
Beyond the preview
Go deeper on ACTRN12624001369516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001369516.